Information  X 
Enter a valid email address

Verseon Corporation (VERS)

  Print      Mail a friend

Thursday 28 March, 2019

Verseon Corporation

Further Update to Admission of Subscription Shares

RNS Number : 2900U
Verseon Corporation
28 March 2019
 

March 28, 2019

 

Verseon Corporation

 

("Verseon" or the "Company")

 

Further Update to Admission of Subscription Shares

 

FREMONT, Calif.-Verseon, a clinical-stage pharmaceutical company developing disruptive life-science technologies to advance global health, today announces that further to the announcement on March 22, 2019, the Directors now expect that Admission of the Subscription Shares, under a separate ISIN for Regulation S restricted stock, will take place on or around Tuesday, April 2, 2019.

 

About Verseon

Verseon Corporation (AIM:VERS) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform to discover new drug candidates that are unlikely to be found using conventional methods. Pairing its computational engines with a comprehensive in-house chemistry and biology workflow, the company has built a growing pipeline of drug programs. Verseon currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

Find Verseon on Twitter and LinkedIn.

- Ends -

For further information, please contact:

 

Verseon Corporation

www.verseon.com

Sebastian Wykeham / Tina Schlafly

+1 (510) 225 9000



Arden Partners (NOMAD and Joint Broker)


Ruari McGirr / Ciaran Walsh / Alex Penney

 +44 (0) 20 7614 5900



Cantor Fitzgerald Europe (Joint Broker) 


Phil Davies

+44 (0) 20 7894 7000

 

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisers)


Henry Harrison-Topham / Jamie Hooper

+44 (0) 20 7466 5000

 

For trade and pharma media enquiries, please contact

Vane Percy & Roberts


Simon Vane Percy

+44 (0) 1737 821 890

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
FUREADDPAEANEEF

a d v e r t i s e m e n t